Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2271-2274

  Lewis, George K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; COMPLEMENTARITY DETERMINING REGION; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIGEN BINDING; B LYMPHOCYTE; CELL MATURATION; COMPLEMENTARITY DETERMINING REGION; DRUG POTENCY; HEAVY CHAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION; VACCINATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER PROGRAM; HUMAN IMMUNODEFICIENCY VIRUS 1;

COMPLEMENTARITY DETERMINING REGIONS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; MODELS, MOLECULAR; SOFTWARE;

EID: 84930387857     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82057     Document Type: Review

References (33)

1. Walker LM, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950): 285-289.
2. Simek MD, et al. Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009;83(14): 7337-7348.
3. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337(6091): 183-186.
4. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity. 2012;37(3): 412-425.
5. Derking R, et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog. 2015;11(3): E1004767.
6. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: Understanding nature's pathways. Immunol Rev. 2013;254(1): 225-244.
7. Derdeyn CA, Moore PL, Morris L. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS. 2014;9(3): 210-216.
8. Willis JR, et al. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J Clin Invest. 2015;125(6): 2523-2531.
9. Kong R, et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol. 2015;89(5): 2659-2671.
10. Julien JP, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013;342(6165): 1477-1483.
11. Pancera M, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014;514(7523): 455-461.
12. Lyumkis D, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013;342(6165): 1484-1490.
13. Merk A, Subramaniam S. HIV-1 envelope glycoprotein structure. Curr Opin Struct Biol. 2013;23(2): 268-276.
14. McLellan JS, et al. Structure of HIV-1 gp120 V1/ V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480(7377): 336-343.
15. Pancera M, et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: Structure-function analysis of two quaternary- specific antibodies that effectively neutralize HIV-1. J Virol. 2010;84(16): 8098-8110.
16. Walker LM, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365): 466-470.
17. Trkola A, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 1995;69(11): 6609-6617.
18. Wu X, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993): 856-861.
19. Huang J, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424): 406-412.
20. Blattner C, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014;40(5): 669-680.
21. Scharf L, et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014;7(3): 785-795.
22. Huang J, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41- gp120 interface. Nature. 2014;515(7525): 138-142.
23. Walker LM, et al. Rapid development of glycanspecific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc Natl Acad Sci U S A. 2011;108(50): 20125-20129.
24. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011 7(1): E1001251.
25. Klein F, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153(1): 126-138.
26. Pejchal R, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A. 2010;107(25): 11483-11488.
27. Briney BS, Willis JR, Crowe JE Jr. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One. 2012;7(5): E36750.
28. Julien JP, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A. 2013;110(11): 4351-4356.
29. Julien JP, et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013;9(5): E1003342.
30. Das R, Baker D. Macromolecular modeling with rosetta. Annu Rev Biochem. 2008;77: 363-382.
31. Doria-Rose NA, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509(7498): 55-62.
32. Kelsoe G, Verkoczy L, Haynes BF. Immune system regulation in the induction of broadly neutralizing HIV-1 antibodies. Vaccines (Basel). 2014;2(1): 1-14.
33. Liu M, et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol. 2015;89(1): 784-798.